Journal Article Ppublish
PubMed: 38763795 DOI: 10.1016/j.dld.2024.04.024
Impact on survival without chemotherapy of local treatments of lung metastasis of colorectal cancers: Analysis on REPULCO cohort.
Dig Liver Dis 56(11):1930-1937
Authors: Lola-Jade Palmieri, Yaniss Belaroussi, Noémie Huchet, Marianne Fonck, Carine Bellera, Veronique Brouste, Nicolas Milhade, Dominique Bechade, Jeanne Lena, Leila Ayache, Xavier Buy, Simon Pernot, Jean Palussière
Affiliations
- Department of Medical Oncology, Institut Bergonié, 229 Cours de L'Argonne, 33000, Bordeaux, France.
- Department of Thoracic Surgery, CHU Haut Leveque, 1 avenue Magellan, 33600, Pessac, France; Department of Clinical and Epidemiological Research, Institut Bergonié, 229 Cours de l'Argonne, 33000, Bordeaux, France.
- Department of Clinical and Epidemiological Research, Institut Bergonié, 229 Cours de l'Argonne, 33000, Bordeaux, France.
- Department of Medical Oncology, Institut Bergonié, 229 Cours de L'Argonne, 33000, Bordeaux, France.
- Department of Radiotherapy, Institut Bergonié, 229 Cours de L'Argonne, 33000, Bordeaux, France.
- Department of Interventional Radiology, Institut Bergonié, 229 Cours de L'Argonne, 33000, Bordeaux, France.
Abstract
BACKGROUND
The impact of local management of pulmonary metastases on the disease course of patients with metastatic colorectal cancer is poorly assessed.
METHODS
REPULCO database was a retrospective cohort on 18 years that included all patients treated for lung metastases from colorectal cancer who received local and/or systemic treatments.
AIMS
Primary objective was overall survival, secondary were progression-free survival and survival without chemotherapy.
RESULTS
Three hundred and fifteen patients were analyzed, 157 with only systemic treatments, 78 with only local treatments, and 80 with local and systemic treatments. Overall survival at 5 years was 26.9% (IC95%: [17.7-36.9]) for systemic treatments only, 61.0% (IC95%: [40.8-76.1]) for local treatments only, and 77.8% (IC95%: [60.1-88.3]) for local and systemic treatments. Progression-free survival at 2 years was 4.8% (IC95%: [2.1-9.2]) for systemic treatment only, 28.3% (IC95%: [17.7-39.9]) for local treatments only, and 21.8% (IC95%: [13.1-31.9]) for local and systemic treatments. Median survival without chemotherapy was 2.99 months (IC95%: [2.33-3.68]) for systemic treatments, 33.97 months (IC95%: [19.06-NA]) for local treatments, and 12.85 months (IC95%: [8.18-21.06]) for local and systemic treatments.
CONCLUSION
Local treatments of lung metastasis led to prolonged survival and allowed long periods of time without chemotherapy in this cohort.
MeSH
Digestive System Diseases, Drug Therapy, Neoplasm Metastasis, Therapeutics, Colorectal Neoplasms, Lung, Disease-Free Survival, Progression-Free Survival, Chemotherapy